Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
ResMed is the global leader in cloud-connected medical devices for sleep apnea, COPD, and other respiratory conditions, with over 20 million patients on its cloud platform. The company generates recurring revenue through device sales (primarily CPAP/BiPAP machines) and high-margin consumables (masks, accessories), with 60%+ gross margins driven by proprietary algorithms, digital health software, and a global installed base creating switching costs.
ResMed operates a razor-razorblade model where initial device sales (50-55% gross margin) create an installed base that drives recurring mask/accessory purchases (65-70% gross margins). Competitive moats include proprietary AutoSet algorithms for pressure titration, 20+ million patient cloud connectivity creating data network effects, and high switching costs from physician familiarity and insurance reimbursement pathways. The company benefits from undiagnosed sleep apnea prevalence (80%+ of cases globally) and aging demographics driving COPD/respiratory conditions. Pricing power stems from clinical efficacy data, insurance reimbursement coverage, and limited competition (primarily Philips, which exited market share due to 2021 recall).
Sleep apnea device unit growth and market share gains (particularly post-Philips recall capturing 5-7% incremental share)
Mask and accessory revenue growth rates (indicates installed base engagement and replacement cycle health)
Operating margin expansion trajectory (target 35%+ long-term vs current 32.7%)
International revenue growth, particularly Europe and Asia-Pacific penetration (40%+ of revenue, higher growth than US)
Competitive dynamics with Philips Respironics recall resolution and market re-entry timeline
Medicare/insurance reimbursement rate changes for sleep apnea diagnostics and CPAP therapy
Medicare reimbursement rate cuts for sleep apnea devices (CMS rate reductions of 5-10% would compress margins given 30-35% US revenue from Medicare)
Competitive pressure from low-cost Chinese manufacturers entering international markets with sub-$200 CPAP devices
Technological disruption from alternative therapies (hypoglossal nerve stimulation devices like Inspire Medical, oral appliances) capturing 5-10% market share from CPAP
Regulatory risk from FDA scrutiny post-Philips recall increasing compliance costs and approval timelines
Philips Respironics market re-entry after resolving recall could recapture 10-15% market share currently held by ResMed
Vertical integration by healthcare systems and payers developing in-house remote monitoring platforms, disintermediating ResMed's AirView software
Amazon and retail channels disrupting traditional DME distribution model with direct-to-consumer CPAP sales
Currency translation headwinds from strong USD given 40%+ international revenue (EUR, AUD, JPY exposure)
Acquisition integration risk from $300M+ annual M&A strategy targeting digital health and software assets
low-to-moderate - Sleep apnea and COPD are medical necessities with 80-90% insurance coverage in developed markets, providing recession resilience. However, elective sleep studies and out-of-pocket device purchases (international markets, cash-pay patients) show modest correlation to consumer confidence and discretionary healthcare spending. Employer-sponsored insurance coverage drives US demand, linking to employment levels.
Rising rates create modest headwind through higher discount rates compressing valuation multiples for growth-oriented med-tech stocks (historically trades at 25-35x P/E). Balance sheet impact minimal given low leverage (0.16 D/E) and $1.7B annual free cash flow. Customer financing programs for uninsured patients see slightly lower uptake in high-rate environments, but represents <5% of revenue.
Minimal direct exposure - revenue primarily from insurance reimbursement and large healthcare distributors with strong credit profiles. Accounts receivable risk concentrated in government payers (Medicare/Medicaid) and national DME chains. No meaningful consumer lending or financing operations.
growth-at-a-reasonable-price (GARP) - Attracts quality-focused growth investors seeking 8-12% revenue growth, 30%+ operating margins, and 90%+ FCF conversion with defensive healthcare characteristics. Dividend yield of 1.0-1.5% appeals to income-focused healthcare allocators. ESG investors value the public health mission (treating undiagnosed sleep apnea reduces cardiovascular risk).
moderate - Beta of 0.8-1.0 with lower volatility than broader med-tech sector due to recurring revenue model and insurance reimbursement stability. Stock experiences 15-20% drawdowns on Medicare reimbursement concerns or competitive threats, but long-term growth trajectory (10-year CAGR of 12%+ revenue) supports valuation recovery.
